Merrimack Pharmaceuticals, Inc.

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new

Ipsen SA ’s Onivyde has beat standard of care for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) in terms of progression-free survival in a pivotal trial but only matched its rival in

Ipsen SA ’s Onivyde (irinotecan liposome injection) has met the primary endpoint of overall survival (OS) in a Phase III trial in untreated pancreatic cancer patients, sparking filing plans, but poten

Ipsen SA ’s Onivyde has flunked the Phase III RESILIENT trial in small-cell lung cancer, raising the stakes for an advanced pancreatic cancer study of the liposomal chemotherapy product set to read ou